- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05379582
The Effect of Early Enteral Nutrition Feeding Process Assisted by Gastrointestinal Ultrasonography
January 27, 2026 updated by: Chinese Medical Association
The Effect of Early Enteral Nutrition Feeding Process Assisted by Gastrointestinal Ultrasonography in Critically Ill Patients
In critical ill patients, feeding protocol is one of the important factor which determines the successful implementation of enteral nutrition(EN).
Acute gastrointestinal injury(AGI) affects feeding tolerance, which greatly determines the successful implementation of feeding protocol.
In our previously study, we found that transabdominal intestinal sonography is helpful to diagnosis AGI.
Thus in this study ,we apply transabdominal gastrointestinal sonography to feeding protocol, to assess the feasibility of gastrointestinal sonography assisted enteral nutrition and its impact on critical ill patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients meeting inclusion and exclusion criteria were randomly assigned to the intervention group and control group.
During the first week of initiation of nutrition, enteral nutrition was conducted according to different procedures to observe the impact of different feeding procedures on clinical indicators
Study Type
Interventional
Enrollment (Actual)
294
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Nanjing Drum Tower Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The age is not less than 18 years
- within 24 hours after entering ICU
- Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 8
- the estimated length of stay in ICU is more than 3 days
- informed consent
Exclusion Criteria:
- The normal anatomy of stomach, small intestine or the right colon was significantly changed (Gastrectomy, esophagectomy, pancreaticoduodenectomy, gastrointestinal bypass surgery, the presence of short bowel syndrome,etc.)
- Uncontrolled gastrointestinal bleeding
- Uncontrolled intestinal obstruction
- Uncontrolled mesenteric vascular disease
- Pregnancy
- breastfeeding
- Received enteral nutrition or parenteral nutrition within 24 hours prior to ICU admission
- Predict death within 48 hours after ICU admission
- Enrolled in this study before.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: control group
Implement nutrition therapy according to existing feeding procedures
|
|
|
Experimental: intervention group
Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound
|
Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target-reaching rate through enteral route
Time Frame: Within first week
|
percentage of participants who reach target calorie through enteral route
|
Within first week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of feeding intolerance
Time Frame: Within first week
|
Within first week
|
|
The application of parenteral nutrition
Time Frame: Within first week
|
Within first week
|
|
The application of prokinetic drugs
Time Frame: Within first week
|
Within first week
|
|
The ues of vasoactive drugs
Time Frame: Within first week
|
Within first week
|
|
Mechanical ventilation
Time Frame: Within first week
|
Within first week
|
|
Continuous renal replacement
Time Frame: Within first week
|
Within first week
|
|
The CRP level
Time Frame: Day0/1/3/5/7
|
Day0/1/3/5/7
|
|
Mortality
Time Frame: Day28、Day60、during hospitalization
|
Day28、Day60、during hospitalization
|
|
ICU length of stay
Time Frame: During ICU stay
|
During ICU stay
|
|
Length of hospital stay
Time Frame: During hospital stay
|
During hospital stay
|
|
Platelet count
Time Frame: Day0,1,3,5,7
|
Day0,1,3,5,7
|
|
Total bilirubin
Time Frame: Day0,1,3,5,7
|
Day0,1,3,5,7
|
|
Serum creatinine
Time Frame: Day0,1,3,5,7
|
Day0,1,3,5,7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: WenKui Yu, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Actual)
October 1, 2023
Study Completion (Actual)
October 1, 2023
Study Registration Dates
First Submitted
April 28, 2022
First Submitted That Met QC Criteria
May 13, 2022
First Posted (Actual)
May 18, 2022
Study Record Updates
Last Update Posted (Actual)
January 28, 2026
Last Update Submitted That Met QC Criteria
January 27, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-050-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.